Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS studyReportar como inadecuado




Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Cardiovascular Diabetology

, 4:7

First Online: 03 June 2005Received: 15 April 2005Accepted: 03 June 2005

Abstract

ObjectiveThe Use of Rosuvastatin versus Atorvastatin iN type 2 diabetes mellitUS URANUS study compared rosuvastatin with atorvastatin for the reduction of low-density lipoprotein cholesterol LDL-C in patients with type 2 diabetes.

MethodsAfter a 6-week dietary run-in, patients aged ≥ 18 years with type 2 diabetes and LDL-C ≥ 3.3 mmol-L were randomised to double-blind treatment with rosuvastatin 10 mg n = 232 or atorvastatin 10 mg n = 233 for 4 weeks. Doses were then titrated up to a maximum of rosuvastatin 40 mg or atorvastatin 80 mg over 12 weeks to achieve the 1998 European LDL-C goal <3.0 mmol-L.

ResultsRosuvastatin reduced LDL-C levels significantly more than atorvastatin during the fixed-dose and titration periods p < 0.0001. Significantly more patients reached the 1998 LDL-C goal with rosuvastatin 10 mg compared with atorvastatin 10 mg at 4 weeks 81% vs 65%, p < 0.001. At 16 weeks, significantly more patients achieved their LDL-C goal with rosuvastatin compared with atorvastatin 94% vs 88%, p < 0.05 and more patients receiving rosuvastatin remained at their starting dose with reduced requirement for dose titration. At 4 weeks, 65% of rosuvastatin patients had reached their 2003 European LDL-C goal < 2.5 mmol-L, compared with 33% of atorvastatin patients p < 0.0001. Both treatments were similarly well tolerated with no unexpected safety concerns.

ConclusionAt the start dose and following dose titration, rosuvastatin was significantly more effective than atorvastatin at reducing LDL-C and achieving European LDL-C goals in patients with type 2 diabetes.

Electronic supplementary materialThe online version of this article doi:10.1186-1475-2840-4-7 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Christian Berne - Annica Siewert-Delle - the URANUS study investigators

Fuente: https://link.springer.com/article/10.1186/1475-2840-4-7







Documentos relacionados